Acute myeloid leukemia cost-effectiveness of therapy

Jump to: navigation, search


Acute myeloid leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute myeloid leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardigram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute myeloid leukemia cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute myeloid leukemia cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute myeloid leukemia cost-effectiveness of therapy

CDC on Acute myeloid leukemia cost-effectiveness of therapy

Acute myeloid leukemia cost-effectiveness of therapy in the news

Blogs on Acute myeloid leukemia cost-effectiveness of therapy

Directions to Hospitals Treating Acute myeloid leukemia

Risk calculators and risk factors for Acute myeloid leukemia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

A limited number of cost-effective studies have been done. For the acute promyelocytic leukemia subtype of acute myeloid leukemia, these studies showed that all-trans retinoic acid-based therapy is more cost-effective than chemotherapy.

Cost-effectiveness of therapy

A limited number of cost-effectiveness studies have been performed in acute myeloid leukemia. One comprehensive cost-effective analysis studied the costs of therapy.

  • The combination of all-trans retinoic acid plus idarubicin was more cost-effective than the combination of all-trans retinoic acid plus cytarabine plus additional chemotherapy.[1]
    • The incremental cost-effective ratio for all-trans retinoic acid plus idarubicin was $2933 per life year saved and $3122 per quality-adjusted life year gained.[1]
  • The combination of all-trans retinoic acid plus arsenic trioxide was more cost-effective than all-trans retinoic acid plus idarubicin.[1]
    • The incremental cost-effective ratio for all-trans retinoic acid plus arsenic trioxide was $4512 per life year saved and $5614 per quality-adjusted life year gained.[1]

References

  1. 1.0 1.1 1.2 1.3 Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M; et al. (2015). "Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States". Clin Lymphoma Myeloma Leuk. 15 (12): 771–7. doi:10.1016/j.clml.2015.07.634. PMC 5028894. PMID 26361645.

Linked-in.jpg